Andreas Wollenberg

76PUBLICATIONS
182CO-AUTHORS
AllergyCancer therapy (excl. chemotherapy and radiation therapy)Disease surveillanceMajor global burdens of diseaseMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (76)

|Oct 22, 2026
Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic Dermatitis.

|Jul 20, 2026
Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial.

|May 21, 2026
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

|Feb 05, 2026
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.

Andrew Blauvelt, H Chih-Ho Hong, Norito Katoh

|Jan 31, 2026
Severity bands for atopic dermatitis measures: Analysis from adult dupilumab randomized clinical trials.

Andreas Wollenberg, Eric L Simpson, Yael A Leshem

|Nov 15, 2025
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema.

David Cohen, Anthony Bewley, Andreas Wollenberg

Pageof 13

Frequent Collaborators

12 joint publications

Jonathan I Silverberg

10 joint publications

Carsten Flohr

9 joint publications

Matthias Augustin

8 joint publications

Annice Heratizadeh